First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2
ConditionMalignant Tumor
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFirst Hospital of China Medical University
About this trial
Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.
Eligibility criteria
Qualifiers
Adults aged 18-80 years
Patients with suspected or histologically confirmed malignant tumors At least one measurable lesion identified by conventional imaging (CT, MRI, or ultrasound)
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Ability to understand the study procedures and provide written informed consent
Disqualifiers
Pregnant or breastfeeding women
Severe hepatic, renal, cardiovascular, or pulmonary dysfunction considered --unsuitable for PET/CT imaging
Known allergy or hypersensitivity to study-related compounds
Patients unable to tolerate PET/CT examination or remain still during image acquisition
Trial design
Treatments tested in this trial
- 68Ga- DOTA-EphA2 PET/CT Imaging of Malignant Tumor
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov